158 related articles for article (PubMed ID: 9651159)
1. Three-dimensional quantitative similarity-activity relationships (3D QSiAR) from SEAL similarity matrices.
Kubinyi H; Hamprecht FA; Mietzner T
J Med Chem; 1998 Jul; 41(14):2553-64. PubMed ID: 9651159
[TBL] [Abstract][Full Text] [Related]
2. Three-dimensional quantitative structure-activity relationships from molecular similarity matrices and genetic neural networks. 1. Method and validations.
So SS; Karplus M
J Med Chem; 1997 Dec; 40(26):4347-59. PubMed ID: 9435904
[TBL] [Abstract][Full Text] [Related]
3. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
Bhongade BA; Gadad AK
J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
[TBL] [Abstract][Full Text] [Related]
4. 3D QSAR studies on protein tyrosine phosphatase 1B inhibitors: comparison of the quality and predictivity among 3D QSAR models obtained from different conformer-based alignments.
Pandey G; Saxena AK
J Chem Inf Model; 2006; 46(6):2579-90. PubMed ID: 17125198
[TBL] [Abstract][Full Text] [Related]
5. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies.
Hou T; Zhu L; Chen L; Xu X
J Chem Inf Comput Sci; 2003; 43(1):273-87. PubMed ID: 12546563
[TBL] [Abstract][Full Text] [Related]
6. Three-dimensional quantitative structure-activity relationship analysis of propafenone-type multidrug resistance modulators: influence of variable selection on test set predictivity.
Fleischer R; Wiese M
J Med Chem; 2003 Nov; 46(23):4988-5004. PubMed ID: 14584949
[TBL] [Abstract][Full Text] [Related]
7. Three-dimensional quantitative structure: activity relationship studies on diverse structural classes of HIV-1 integrase inhibitors using CoMFA and CoMSIA.
Nunthaboot N; Tonmunphean S; Parasuk V; Wolschann P; Kokpol S
Eur J Med Chem; 2006 Dec; 41(12):1359-72. PubMed ID: 17002889
[TBL] [Abstract][Full Text] [Related]
8. A comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) of anthranilamide derivatives that are multidrug resistance modulators.
Labrie P; Maddaford SP; Fortin S; Rakhit S; Kotra LP; Gaudreault RC
J Med Chem; 2006 Dec; 49(26):7646-60. PubMed ID: 17181148
[TBL] [Abstract][Full Text] [Related]
9. CoMFA and CoMSIA 3D QSAR analysis on N1-arylsulfonylindole compounds as 5-HT6 antagonists.
Doddareddy MR; Cho YS; Koh HY; Pae AN
Bioorg Med Chem; 2004 Aug; 12(15):3977-85. PubMed ID: 15246074
[TBL] [Abstract][Full Text] [Related]
10. 3D QSAR studies on T-type calcium channel blockers using CoMFA and CoMSIA.
Doddareddy MR; Jung HK; Cha JH; Cho YS; Koh HY; Chang MH; Pae AN
Bioorg Med Chem; 2004 Apr; 12(7):1613-21. PubMed ID: 15028254
[TBL] [Abstract][Full Text] [Related]
11. Predicting anti-HIV activity of 1,3,4-thiazolidinone derivatives: 3D-QSAR approach.
Ravichandran V; Prashantha Kumar BR; Sankar S; Agrawal RK
Eur J Med Chem; 2009 Mar; 44(3):1180-7. PubMed ID: 18687505
[TBL] [Abstract][Full Text] [Related]
12. Systematic statistical comparison of comparative molecular similarity indices analysis molecular fields for computer-aided lead optimization.
Dias MM; Mittal RR; McKinnon RA; Sorich MJ
J Chem Inf Model; 2006; 46(5):2015-21. PubMed ID: 16995732
[TBL] [Abstract][Full Text] [Related]
13. 3D-QSAR studies for the binding affinity toward (R, S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)-propionic acid receptor.
Sharma RN; Thakar H; Vasu KK; Chaturvedi SC
Acta Pharm; 2008 Sep; 58(3):335-45. PubMed ID: 19103570
[TBL] [Abstract][Full Text] [Related]
14. 3D-QSAR studies of Checkpoint Kinase Weel inhibitors based on molecular docking, CoMFA and CoMSIA.
Yi P; Fang X; Qiu M
Eur J Med Chem; 2008 May; 43(5):925-38. PubMed ID: 17698256
[TBL] [Abstract][Full Text] [Related]
15. 3D-QSAR CoMFA/CoMSIA studies on Urokinase plasminogen activator (uPA) inhibitors: a strategic design in novel anticancer agents.
Bhongade BA; Gadad AK
Bioorg Med Chem; 2004 May; 12(10):2797-805. PubMed ID: 15110861
[TBL] [Abstract][Full Text] [Related]
16. Insights into the structural requirements of farnesyltransferase inhibitors as potential anti-tumor agents based on 3D-QSAR CoMFA and CoMSIA models.
Puntambekar DS; Giridhar R; Yadav MR
Eur J Med Chem; 2008 Jan; 43(1):142-54. PubMed ID: 17448576
[TBL] [Abstract][Full Text] [Related]
17. Rational design based on bioactive conformation analysis of pyrimidinylbenzoates as acetohydroxyacid synthase inhibitors by integrating molecular docking, CoMFA, CoMSIA, and DFT calculations.
He YZ; Li YX; Zhu XL; Xi Z; Niu C; Wan J; Zhang L; Yang GF
J Chem Inf Model; 2007; 47(6):2335-44. PubMed ID: 17887745
[TBL] [Abstract][Full Text] [Related]
18. Pharmacophore-based 3D-QSAR of HIF-1 inhibitors.
Chung JY; Pasha FA; Cho SJ; Won M; Lee JJ; Lee K
Arch Pharm Res; 2009 Mar; 32(3):317-23. PubMed ID: 19387572
[TBL] [Abstract][Full Text] [Related]
19. Highly predictive CoMFA and CoMSIA models for two series of stromelysin-1 (MMP-3) inhibitors elucidate S1' and S1-S2' binding modes.
Amin EA; Welsh WJ
J Chem Inf Model; 2006; 46(4):1775-83. PubMed ID: 16859309
[TBL] [Abstract][Full Text] [Related]
20. The comparative molecular surface analysis (CoMSA) with modified uniformative variable elimination-PLS (UVE-PLS) method: application to the steroids binding the aromatase enzyme.
Polanski J; Gieleciak R
J Chem Inf Comput Sci; 2003; 43(2):656-66. PubMed ID: 12653535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
